Amneal Pharmaceuticals price target raised to $10 from $8 at Barclays

Barclays raised the firm’s price target on Amneal Pharmaceuticals to $10 from $8 and keeps an Overweight rating on the shares. The company reported a strong Q2 print, with growth across all three segments beating expectations, the analyst tells investors in a research note. The firm believes Amneal “is still in the early innings of a long growth phase.”